• Alias: T-DM1
    • A HER2-antibody–drug conjugate that incorporates the HER2 targeted actions of trastuzumab with the microtubule inhibitor DM1 (a maytansine derivative). The conjugate, which is linked via a stable thioether linker, allows for selective delivery into HER2 overexpressing cells, resulting in cell cycle arrest and apoptosis.
    • FDA approved for HER2-positive metastatic breast cancer patients who have previously had trastuzumab
    • Recommended dose: 3.6 mg/kg IV every 3 weeks over 90 minutes with first dose, then may decrease to 30 minutes if tolerated
    • Half-life: â™4 days
    • Common side effects: Fatigue, headache, neuropathy, skin usea, abdominal pain, muscle pain, arthralgias, cough, fever
    Other topics in Targeted and Immunotherapy Agents